Products for Research Use Only

Vanzacaftor-d4

CAT: 0804-HY-145603SSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145603SSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor. Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases[1][2].
Product Name Alternative
VX-121-d4
UNSPSC
12352005
Target
CFTR; Chloride Channel; Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Smiles
CC1(C[C@@]([H])(C([2H])([2H])N1C2=NC(N3C=CC(OC([2H])(CC4C5(C46CC6)CC5)[2H])=N3)=CC=C27)CCC/N=C8NC(S(=O)(NC7=O)=O)=CC=C\8)C
Molecular Formula
C32H35D4N7O4S
Molecular Weight
621.79
References & Citations
[1]Uluer AZ, et al. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials[J]. Lancet Respir Med. 2023 Jun;11 (6) :550-562.|[2]Kolski-Andreaco A, et al. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator (CFTR) correctors VX-445 and VX-121[J]. J Clin Invest. 2024 Jul 2:e176328.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products